Drug intelligence / Profile preview

fluconazole + azithromycin + secnidazole

Development stage
Unknown
Lead developer
Chem Med Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

fluconazole + azithromycin + secnidazole is a fixed-dose combination (FDC) anti-infective therapy developed by Chem Med Pharmaceuticals for the treatment of mixed vaginal infections. This 'combikit' approach is designed for the syndromic management of vaginal discharge, addressing fungal, bacterial, and protozoal pathogens simultaneously. Fluconazole, a triazole antifungal, inhibits the enzyme lanosterol 14-alpha demethylase, disrupting fungal cell membrane synthesis. Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Secnidazole is a nitroimidazole derivative that enters the cell and is reduced to intermediates that cause DNA strand breakage, effectively treating anaerobic bacteria and protozoa like Trichomonas vaginalis. The combination is typically administered as a single-day oral regimen to ensure high patient compliance.

Brand names
Trizolac
Other names
Fluconazole, Azithromycin & Secnidazole TabletsFAS KitFluconazole 150mg / Azithromycin 1gm / Secnidazole 1gm combinationFluconazole, Azithromycin, Secnidazole
02

Targets

CYP51A1 (Sterol 14α-demethylase)NeuraminidaseBacterial 50S ribosomal subunit

Beyond the preview

Go deeper on fluconazole + azithromycin + secnidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluconazole + azithromycin + secnidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call